Clinical Trials

Enrolling Studies – To inquire about any of the studies, please email: Derm.Research@BrownPhysicians.org

MedImmune 3506

PI:
Jennie Muglia, MD

Sponsor:
Astra Zeneca

Study Phase:
Phase 2

Indicated For:
Adults with Moderate to Severe AD (Patient may be randomized to 1 of 5 groups 3 are the active drug and 2 placebo based on different dosages in a 3:1:1:1:2 ratio)

Study Drug:
Injection at study visits

Inclusion Criteria:
The study is looking for participants between the ages of 18- 65 years old with atopic dermatitis also known as eczema for at least 1 year. This study is for patients that have tried topical steroids that have not worked in the past 6 months and have moderate to severe atopic dermatitis/eczema.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

CTP-543

PI:
Carlos Wambier, PhD, MD

Sponsor:
Concert Pharmaceuticals

Study Phase:
Phase 2

Indicated For:
Adults with Moderate to Severe Alopecia Areata (at least 50% hair loss)
(Patients will be randomized in a 3:5:2 ratio (12 mg BID:8 mg BID:placebo)

Study Drug:
Tablets (BID)

Inclusion Criteria:
The study is looking for participants between the ages of 18- 65 years old with moderate to severe hair loss and have been diagnosed with alopecia areata. The patients should have at least 50% hair loss on the scalp with hair loss on the top of the scalp.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

Otezla Study

PI:
Abrar Qureshi, MD

Sponsor:
Amgen

Study Phase:
Phase 4

Indicated For:
Adults with Early, oligoarticular
psoriatic arthritis despite initial stable treatment with either non-steroidal anti-inflammatory
drugs (NSAIDs) and/or more than 1 conventional synthetic disease-modifying antirheumatic
drugs (DMARD)
(Subjects will be randomly assigned in a 2:1 ratio to either apremilast 30 mg BID
or placebo, but all patients get study drug by Week 24)

Study Drug:
Tablets (BID)

Inclusion Criteria:
The study is looking for participants between the ages of 18 and older with a diagnosis of psoariatic arthritis no more than 24 months prior. Patients will need 1-4 swollen and tender joints to apply.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

INTERCEPT

PI:
Abrar Qureshi, MD

Sponsor:
Novartis

Study Phase:
Phase 4

Indicated For:
Adults with Moderate to Severe Plaque Psoriasis (more than or equal 10 % BSA)
(randomized in a 2:1 ratio to treatment with either secukinumab 300 mg s.c. or placebo. An option to transition to the commerically available Cosentyx is an option at the end of the study)

Study Drug:
Injection – self-administration with training at home , or can receive in the clinic (if desired)

Inclusion Criteria:
The study is looking for participants between the ages of 18 and older with a diagnosis of plaque psoriasis arthritis of at least 6 months. This study is for patients that have not had a good response in the past to topical corticosteroid creams/ ointments.

Status:
Enrolling Soon/ accepting potential subjects for pre-screening

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

HS0003

PI:
Carlos Wambier, MD, PhD

Sponsor:
UCB Biopharma

Study Phase:
Phase 3

Indicated For:
Adults with Moderate or Severe HS in at least 2 anatomical areas
(randomized in a 2:2:2:1 ratio of bimekizumab vs. placebo)

Study Drug:
Injection – administered at Study Visits

Inclusion Criteria:
The study is looking for participants between the ages of 18 and older with a diagnosis of hidradenitis suppurativa (HS) of at least 6 months. This study is for patients that have not had a good response in the past to antibiotics. Patient will need HS areas on at least 2 parts of the body, and have 5 or more lesions.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

ILUMYA

PI:
Carlos Wambier, PhD, MD

Sponsor:
Sun Pharma

Study Phase:
Investigator Initiated

Indicated For:
Moderate to Severe Psoriasis (age 35 or older)

Study Drug:
Injection – administered at Study Visits

Inclusion Criteria:
This study is for patients 35 years of age or older with moderate to severe psoriasis ands are willing to go on ILUMYA for the first time to manage the symptoms of psoriasis. Patients are also needed for this study that have psoriasis, and will not be going on ILUMYA for a one time blood draw at the beginning of the study.

Status:
Enrolling Soon/ accepting potential subjects for pre-screening

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

Corrona Registry

PI:
Jennie Muglia, MD

Sponsor:
Corrona LLC

Study Phase:
Registry

Indicated For:
Psoriasis and starting or switching to a new systemic psoriasis treatment within 12 months

Study Drug:
Questionnaires/ Medical record

Inclusion Criteria:
This registry is for patients that are 18 years of age or older, who are coming in for a routine appointment with their Dermatologist and will be starting a new FDA approved biologic.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

STIGMA

PI:
Lionel Bercovitch, MD

Sponsor:
The Pediatric Dermatology Research Alliance

Study Phase:
n/a

Indicated For:
Pediatric population with chronic skin condition (Parent and Child Questionnaires) – Ages 8-17 years old

Study Drug:
Questionnaire (Parent and Child)

Inclusion Criteria:
This is a one time study for children with chronic skin conditions from ages 8-17 years of age. The parent/guardian and child/ teen will be asked to complete questionnaires to better understand dermatology/ skin disorders in children and teens.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.